Axsome Therapeutics Inc (AXSM)

[BioSpecialist]

There are NO approved drugs for AD agitation if AXS-05 is successfull in phase 3 then it is a potential Blockbuster . Acadia (ACAD) which has a valuation of above $3 billion also working on this indication but there 2-3 years behind Axsome .

http://axsome.com/axs-05/agitation-in-patients-with-alzheimers-disease-ad/

There are currently no therapies approved by the FDA for the treatment of agitation in patients with AD.


Alzheimer’s Disease Agitation (AD Agitation)

According to the Alzheimer’s Association, around 5.4 million people in the United States are living with Alzheimer’s disease and approximately half are diagnosed with the disease. Studies suggest that 40 to 50 percent of patients diagnosed with Alzheimer’s disease in the United States exhibit agitation. AD Agitation is characterized by verbal aggression, physical aggression, and excessive motor activities. These behavioral symptoms have been associated with more rapid cognitive decline, greater caregiver burden, and earlier institutionalization.